Residency · Residency · Obstetrics Gynecology
Teratology and Medication Safety in Pregnancy
Principles of Teratogenicity
Definitions and Historical Context
A teratogen is any agent -- whether a drug, chemical, infection, or radiation -- that causes structural or functional abnormalities in the developing embryo or fetus. The thalidomide disaster of the 1960s was the catalyst for modern teratology and drug regulation in pregnancy. Only about 30 drugs are proven human teratogens, but data remain limited for the vast majority of medications.
Critical Periods of Susceptibility
Teratogenic risk varies dramatically with the timing of exposure. During the pre-implantation period (days 0 to 14), the "all-or-none" principle applies: exposure either causes pregnancy loss or has no effect. The embryonic period (weeks 3 to 8) is the time of organogenesis and carries the highest risk for major structural malformations. Specific organ vulnerabilities are tightly time-bound: the heart is most vulnerable from days 21 to 56, the neural tube from days 21 to 28, the limbs from days 24 to 36, and the palate from weeks 6 to 9. During the fetal period (weeks 9 to 40), growth and functional maturation predominate, and exposure tends to cause growth restriction, functional deficits, or minor anomalies rather than major structural defects. The CNS remains vulnerable throughout the entire pregnancy.
Dose-Response and Threshold Concepts
Most teratogens exhibit a dose-response relationship, and for many agents a threshold dose exists below which no teratogenic effect occurs. Duration and timing of exposure interact with dose to determine overall risk. Genetic susceptibility -- both maternal and fetal -- further modulates teratogenic risk.
<image>Diagram showing the critical periods of human embryonic development by organ system, with a timeline from weeks 1-38 illustrating windows of vulnerability for each organ to teratogenic insult</image>
FDA Pregnancy and Lactation Labeling
Former Letter Category System (A, B, C, D, X)
The old letter category system was oversimplified and often misinterpreted by clinicians. It led to unnecessary drug avoidance, particularly for Category C and D medications. The system was officially retired in 2015.
Current PLLR (Pregnancy and Lactation Labeling Rule)
The PLLR was implemented in June 2015 for new drugs and is being phased in for older drugs. It contains three subsections: Pregnancy, Lactation, and Females and Males of Reproductive Potential. Each subsection provides narrative summaries of human data, animal data, and pharmacokinetic considerations, along with a risk summary, clinical considerations, and data sections. The key shift is that clinicians must now interpret nuanced information rather than rely on a single letter grade.
Known Teratogens and Their Effects
Anticonvulsants
Valproic acid carries a 7 to 10% malformation rate, including neural tube defects (1 to 2%), craniofacial anomalies, cardiac defects, and limb anomalies. It also causes dose-dependent neurodevelopmental effects including lower IQ and increased autism risk, and is contraindicated in pregnancy when alternatives exist. Carbamazepine has an approximately 3% malformation rate with NTDs at 0.5 to 1% and craniofacial anomalies. Phenytoin causes fetal hydantoin syndrome, characterized by craniofacial anomalies, nail and digit hypoplasia, and growth restriction. Topiramate increases the risk of oral clefts 2 to 3 times above baseline. Levetiracetam and lamotrigine are considered safer alternatives, though lamotrigine requires dose adjustment in pregnancy due to increased clearance.
| Anticonvulsant | Malformation Rate | Key Defects | Pregnancy Recommendation |
|---|---|---|---|
| Valproic acid | 7-10% | NTDs, craniofacial, cardiac, neurodevelopmental | Contraindicated; switch to alternatives |
| Carbamazepine | ~3% | NTDs (0.5-1%), craniofacial anomalies | Use if necessary; high-dose folate |
| Phenytoin | Variable | Fetal hydantoin syndrome | Avoid if alternatives exist |
| Topiramate | 2-3x baseline clefts | Oral clefts | Avoid if alternatives exist |
| Lamotrigine | ~2-3% (near baseline) | No consistent pattern | Preferred; adjust dose for clearance |
| Levetiracetam | ~2-3% (near baseline) | No consistent pattern | Preferred alternative |
Retinoids
Isotretinoin is highly teratogenic, with a malformation rate exceeding 25%, producing CNS, craniofacial, cardiac, and thymic anomalies. The iPLEDGE program mandates pregnancy prevention, and the drug must be discontinued at least one month before conception. Acitretin requires a three-year washout before conception.
ACE Inhibitors and ARBs
In the second and third trimesters, these drugs cause renal tubular dysgenesis, oligohydramnios, pulmonary hypoplasia, and skull ossification defects. First-trimester risk is debated, but switching to labetalol or nifedipine before conception is best practice. These medications should be discontinued as soon as pregnancy is confirmed.
Warfarin
First-trimester exposure between weeks 6 and 9 causes warfarin embryopathy, characterized by nasal hypoplasia and stippled epiphyses. CNS anomalies can occur with exposure at any gestational age. The standard approach is to switch to low-molecular-weight heparin or unfractionated heparin in early pregnancy, though warfarin may be considered in the second trimester for patients with mechanical heart valves after careful risk-benefit discussion.
Methotrexate / Mycophenolate
Methotrexate causes aminopterin/methotrexate syndrome with craniosynostosis, limb anomalies, and growth restriction. Mycophenolate produces ear, facial, cardiac, and renal anomalies. Methotrexate should be discontinued three months before conception, and mycophenolate six weeks before.
Lithium
Lithium increases the risk of Ebstein anomaly, though the absolute risk is low (approximately 0.1 to 0.2% compared to a baseline of 0.005%). Fetal echocardiography is recommended at 18 to 22 weeks. Dose adjustment is needed as GFR and volume of distribution change during pregnancy. The decision to continue lithium must balance fetal risk against the stability of maternal bipolar disorder.
Alcohol and Recreational Substances
Alcohol causes fetal alcohol spectrum disorder (FASD), with no proven safe threshold. Fetal alcohol syndrome includes facial dysmorphology, growth restriction, and CNS dysfunction. Cocaine increases the risk of placental abruption, vasoconstriction-related anomalies, and growth restriction. Opioids cause neonatal abstinence syndrome but are not associated with structural teratogenicity, though they produce significant neonatal morbidity.
<image>Illustration comparing the facial features of fetal alcohol syndrome (smooth philtrum, thin upper lip, small palpebral fissures) with normal facial anatomy in a neonate</image>
Commonly Encountered Medication Decisions
SSRIs and Antidepressants
Paroxetine carries a possible small increase in cardiac defects (relative risk approximately 1.5) and should be avoided if alternatives exist. Sertraline and citalopram are generally preferred in pregnancy with minimal teratogenic signal. Third-trimester SSRI exposure can cause neonatal adaptation syndrome (jitteriness, respiratory distress, feeding difficulty), which is usually self-limited. The risk of persistent pulmonary hypertension of the newborn (PPHN) is very low in absolute terms (approximately 0.3%), and the data remain conflicting. Critically, untreated maternal depression carries significant risks including preterm birth, low birth weight, impaired bonding, and suicide -- the treatment benefits often outweigh the theoretical fetal risks.
Antihypertensives
Labetalol and nifedipine are first-line agents for chronic hypertension in pregnancy. Methyldopa is safe but less efficacious and is falling out of favor. ACE inhibitors and ARBs are contraindicated. Atenolol is associated with growth restriction and should be avoided.
Antibiotics
Penicillins, cephalosporins, and azithromycin are safe. Nitrofurantoin is safe but should be avoided near term due to the risk of neonatal hemolytic anemia. Tetracyclines should be avoided after 16 weeks (tooth discoloration and bone growth inhibition). Fluoroquinolones are avoided due to cartilage damage in animal studies. Trimethoprim, a folate antagonist, should be avoided in the first trimester. Metronidazole is safe in pregnancy despite historical concerns, with no teratogenic signal.
| Antibiotic Class | Safety in Pregnancy | Notes |
|---|---|---|
| Penicillins | Safe | First-line for many infections |
| Cephalosporins | Safe | First-line for many infections |
| Azithromycin | Safe | Preferred macrolide |
| Nitrofurantoin | Safe (avoid near term) | Risk of neonatal hemolytic anemia at term |
| Tetracyclines | Avoid after 16 weeks | Tooth discoloration, bone growth inhibition |
| Fluoroquinolones | Avoid | Cartilage damage in animal studies |
| Trimethoprim | Avoid in first trimester | Folate antagonist |
| Metronidazole | Safe | No teratogenic signal despite historical concerns |
Thyroid Medications
Levothyroxine is safe, though the dose often needs a 30 to 50% increase in pregnancy. Methimazole is associated with aplasia cutis and choanal or esophageal atresia in the first trimester. The recommended approach is to switch to PTU in the first trimester, then consider switching back to methimazole in the second trimester to avoid PTU's hepatotoxicity risk.
NSAIDs
In the first trimester, there is a possible slight increase in miscarriage risk, though the data are conflicting. After 32 weeks, NSAIDs can cause premature closure of the ductus arteriosus and oligohydramnios. Per updated FDA guidance from 2020, NSAIDs should be avoided after 20 weeks. Acetaminophen remains the first-line analgesic and antipyretic.
Shared Decision-Making Framework
Principles of Counseling
Effective counseling quantifies absolute risks rather than relying solely on relative risks. Drug risk should be compared against the baseline malformation rate of 3% for any pregnancy. The risk of untreated maternal disease must be considered alongside medication risk. Reliable resources include Reprotox, TERIS, LactMed, and MotherToBaby. Maternal-fetal medicine consultation should be involved for complex cases.
Documentation
The discussion of risks, benefits, and alternatives should be documented thoroughly. The patient's understanding and informed decision should be noted. Appropriate fetal surveillance should be arranged if a potentially teratogenic medication is continued.
<image>Flowchart for medication counseling in pregnancy showing the decision pathway: assess indication severity, review teratogenic risk data, consider alternative agents, discuss with patient using absolute risk numbers, plan appropriate fetal surveillance if medication is continued</image>
Radiation Exposure in Pregnancy
The threshold for concern with diagnostic imaging is a cumulative fetal dose exceeding 50 mGy (5 rad). Most diagnostic studies fall well below this threshold: a chest X-ray delivers approximately 0.01 mGy, a CT head less than 0.05 mGy, and a CT abdomen/pelvis 10 to 35 mGy. MRI without gadolinium is safe at all gestational ages. Gadolinium crosses the placenta and has been associated with adverse neonatal outcomes, so it should be avoided unless critical. Nuclear medicine studies require individualized assessment of fetal dose. Clinically necessary imaging should never be withheld based on pregnancy status alone.
| Imaging Study | Estimated Fetal Dose | Safety in Pregnancy |
|---|---|---|
| Chest X-ray | ~0.01 mGy | Safe |
| CT head | <0.05 mGy | Safe |
| CT abdomen/pelvis | 10-35 mGy | Generally safe; below threshold |
| MRI without gadolinium | None (non-ionizing) | Safe at all gestational ages |
| MRI with gadolinium | N/A | Avoid unless critical |
| Nuclear medicine | Variable | Individualized assessment required |
| Threshold for concern | >50 mGy cumulative | — |
Clinical Pearls
The background malformation rate is approximately 3%, and drug risks should always be contextualized against this baseline. The old "Category C" did not mean "dangerous" -- most drugs placed there simply lacked adequate human data. Abrupt medication discontinuation can be more dangerous than continuing therapy, particularly in epilepsy, bipolar disorder, and depression. Timing of exposure matters as much as the agent itself, and first-trimester counseling requires knowledge of exact gestational age and organogenesis windows. Preconception planning is the best teratogen prevention strategy, as it allows medication regimens to be optimized before conception. LactMed should always be checked for breastfeeding compatibility, since many drugs considered unsafe in pregnancy are safe during lactation.
References
- ACOG Practice Bulletin No. 236: Teratology (2021)
- Briggs GG, Freeman RK. Drugs in Pregnancy and Lactation. 12th ed. Wolters Kluwer; 2022
- FDA Pregnancy and Lactation Labeling Rule (PLLR), 2015
- Bromley RL et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014
- MotherToBaby (Organization of Teratology Information Specialists): mothertobaby.org
- Reprotox Database: reprotox.org
- Huybrechts KF et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370:2397-2407
